One hundred patients have been randomly assigned in Nuvaira’s pivotal AIRFLOW-3 clinical trial that will investigate the efficacy and safety of targeted lung denervation (TLD) to reduce exacerbations, or episodes of symptom worsening, of chronic obstructive pulmonary disease (COPD) in patients on optimal medical care. Because of the…
Lung function and quality of life remained stable over three years of follow-up among people with chronic obstructive pulmonary disease (COPD) treated with targeted lung denervation (TLD) — a new therapy developed by Nuvaira — according to the results of a clinical trial. That trial, called AIRFLOW-1 (…
Nuvaira, a medical device company, announced the upcoming publication of several scientific studies detailing the findings of clinical trials that assessed the safety and effectiveness of its Targeted Lung Denervation (TLD) therapy in patients with chronic obstructive pulmonary disease (COPD). Nuvaira’s proprietary TLD therapy works to disrupt pulmonary…
Nuvaira, a medical device company, announced it has secured $79 million to support the AIRFLOW-3 clinical trial to assess the company’s new targeted lung denervation (TLD) system, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). COPD includes a group of diseases characterized by chronic airway obstruction…
Treatment of chronic obstructive pulmonary disease (COPD) with a minimally invasive investigative procedure called targeted lung denervation (TLD) is feasible, safe, and was found to improve lung function, according to researchers. Their study, “Long-term safety of bilateral targeted lung denervation in patients with COPD,” was published in…
Get regular updates to your inbox.